Literature DB >> 7473876

Glial fibrillary acidic protein mRNA isotypes: expression in vitro and in vivo.

E Galea1, P Dupouey, D L Feinstein.   

Abstract

Glial fibrillary acidic protein (GFAP) and its mRNA, primarily expressed in astrocytes, are also expressed in peripheral nervous system Schwann cells as well as in certain non-neural tissues. Schwann cells express a GFAP mRNA (GFAP-beta) which differs from the CNS-type mRNA (GFAP-alpha) by the presence of an extended 5' untranslated region. We have developed a polymerase chain reaction assay which allows distinction of these two GFAP mRNAs, as well as quantitative analysis of their levels. In the cultured rat Schwannoma cell line RT4-D6, GFAP-beta was the major GFAP mRNA species, accounting for at least 75% of total GFAP (alpha + beta) mRNA. GFAP-beta was also detected in primary rat astrocyte cultures, where it constituted approximately 5% of the total GFAP mRNA, as well as in RNA samples prepared from normal rat cerebral cortex, and from hamster and human brain. In rat cortex, the temporal expression of GFAP-beta mRNA paralleled that of total GFAP mRNA, with plateau levels reached between postnatal days 15 and 20. In astrocyte cultures, the relative levels of GFAP-alpha and -beta mRNAs were differentially regulated by exposure to interferon-gamma (10 to 25 units/ml), which caused an increase in GFAP-beta levels while at the same time no change or a small decrease in total GFAP levels. In rat brain cortical slices, 4 hr exposure to 25 units/ml interferon-gamma decreased total GFAP mRNA levels over tenfold, while GFAP-beta levels were unaffected. These data indicate that a second form of the GFAP mRNA is expressed in astrocytes both in vivo and in vitro and provide evidence for independent regulation of these two GFAP mRNA species.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7473876     DOI: 10.1002/jnr.490410404

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  14 in total

Review 1.  GFAP and its role in Alexander disease.

Authors:  Roy A Quinlan; Michael Brenner; James E Goldman; Albee Messing
Journal:  Exp Cell Res       Date:  2007-04-06       Impact factor: 3.905

Review 2.  Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker.

Authors:  Zhihui Yang; Kevin K W Wang
Journal:  Trends Neurosci       Date:  2015-05-11       Impact factor: 13.837

3.  GFAPbeta mRNA expression in the normal rat brain and after neuronal injury.

Authors:  D F Condorelli; V G Nicoletti; P Dell'Albani; V Barresi; A Caruso; S G Conticello; N Belluardo; A M Giuffrida Stella
Journal:  Neurochem Res       Date:  1999-05       Impact factor: 3.996

4.  Alterations in levels of mRNAs coding for glial fibrillary acidic protein (GFAP) and vimentin genes in the central nervous system of hens treated with diisopropyl phosphorofluoridate (DFP).

Authors:  T V Damodaran; M B Abou-Donia
Journal:  Neurochem Res       Date:  2000-06       Impact factor: 3.996

5.  Sarin causes early differential alteration and persistent overexpression in mRNAs coding for glial fibrillary acidic protein (GFAP) and vimentin genes in the central nervous system of rats.

Authors:  Tirupapuliyar V Damodaran; Magdalena A Bilska; Ali A Rahman; Mohamed B Abou-Doni
Journal:  Neurochem Res       Date:  2002-05       Impact factor: 3.996

Review 6.  Regulation of GFAP Expression.

Authors:  Michael Brenner; Albee Messing
Journal:  ASN Neuro       Date:  2021 Jan-Dec       Impact factor: 4.146

7.  Computational characterization of 3' splice variants in the GFAP isoform family.

Authors:  Sarah E Boyd; Betina Nair; Sze Woei Ng; Jonathan M Keith; Jacqueline M Orian
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

8.  Glioprotective effects of Ashwagandha leaf extract against lead induced toxicity.

Authors:  Praveen Kumar; Raghavendra Singh; Arshed Nazmi; Dinesh Lakhanpal; Hardeep Kataria; Gurcharan Kaur
Journal:  Biomed Res Int       Date:  2014-05-28       Impact factor: 3.411

9.  Integration of proteomics, bioinformatics, and systems biology in traumatic brain injury biomarker discovery.

Authors:  J D Guingab-Cagmat; E B Cagmat; R L Hayes; J Anagli
Journal:  Front Neurol       Date:  2013-05-31       Impact factor: 4.003

Review 10.  Blood Biomarkers for Evaluation of Perinatal Encephalopathy.

Authors:  Ernest M Graham; Irina Burd; Allen D Everett; Frances J Northington
Journal:  Front Pharmacol       Date:  2016-07-13       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.